Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

iCell® Neurons Enable Alzheimer’s Disease Modeling

Published: Thursday, April 25, 2013
Last Updated: Wednesday, April 24, 2013
Bookmark and Share
Research demonstrate potential use of iCell® Neurons in high throughput screening at GlaxoSmithKline.

Cellular Dynamics International (CDI) has announced the publication of research demonstrating the use of human iPSC-derived iCell® Neurons to model Alzheimer’s disease (AD) and how they may be used in high throughput drug screening.

This research was performed by the lab of Zhong Zhong, Ph.D., head of discovery in the regenerative medicine group within GlaxoSmithKline (GSK), and recently published online in Stem Cell Research (DOI 10.1016/j.scr.2012.11.005).

The GSK researchers used CDI’s commercially available iCell Neurons, comprised of human neurons with characteristic forebrain markers, to model neuronal loss in human AD brains by exposing them to β-amyloid 1-42 (Aβ1-42), a peptide known to be associated with AD.

Aβ1-42 builds up in the brains of those susceptible to the disease and acts as a plaque that causes progressive memory loss and cognitive decline.

Because iCell Neurons meet tight quality standards and are available commercially in large quantities, the researchers used this AD cellular model to screen hundreds of compounds and ultimately identified several small molecules that inhibited the Aβ1-42 toxicity.

This is the first known use of human iPSCs to model Alzheimer’s disease through Aβ1-42 toxicity in a drug screen and demonstrates the value of commercial-scale quantities of human iPSC-derived cells for use in disease modeling, drug discovery, and target validation.

“Prior to iCell Neurons, the research models available to study AD included mice, human postmortem tissues, and immortalized neuronal cell lines. These models all have severe physiologic and genetic limitations,” said Emile Nuwaysir, chief operating officer of CDI and co-author on the paper.

Nuwaysir continued, “To make rapid progress in AD research, it is critical to have a cellular model that accurately recapitulates normal and disease pathology. We were excited to work with a team as talented as Dr. Zhong’s to perform this study, which demonstrated that when you have a physiologically relevant and reproducible system like iCell Neurons as the basis for your screening platform, you can make rapid and dramatic discoveries.”

Robert Palay, chief executive officer of CDI, added, “CDI’s iCell Neurons exhibit true functional human biology. This study demonstrated the potential of high throughput screening on iCell Neurons in identifying novel therapeutic compounds. The work contained in this paper is just another example confirming that CDI’s ability to supply our customers with fully functional, standardized human cells enables pharmaceutical scientists to quickly discover new drug candidates, particularly for challenging pathologies such as neurodegenerative diseases.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

CDI and Roche Transition Early Access Collaboration into a Standard Supply Agreement Ahead of Schedule
iCell Cardiomyocytes, induced pluripotent stem cell-derived human heart cells, will be incorporated into Roche’s drug development decision-making process.
Wednesday, March 23, 2011
Cellular Dynamics Partners with iPS Academia Japan to In-License Seminal iPS Cell Patent Portfolio
Companies announce a nonexclusive licensing agreement for the seminal iPSC patent portfolio arising out of the work of Dr. Shinya Yamanaka.
Monday, May 10, 2010
Cellular Dynamics Raises $40.6 MM to Revolutionize Pharma Drug Research
The financing enables the company to increase production capacity for its iCell™ Cardiomyocytes and to launch additional human tissue cell products.
Thursday, April 29, 2010
CDI’s iCell™ Cardiomyocytes Named to MIT Technology Review’s Annual 10 Emerging Technologies List
iCell Cardiomyocytes are first human IPSC-derived cell type launched for high throughput drug discovery and toxicity testing.
Friday, April 23, 2010
Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
Greater than 90 percent cell type purification enabled through exclusively licensed technology.
Friday, July 17, 2009
Cellular Dynamics International Licenses Key Patent Portfolio Surrounding Cardiovascular Progenitor Cells
The exclusive license covers differentiation of stem cells into all cell types of the human heart.
Wednesday, June 03, 2009
Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!